EP0820311A4 - Transplantation de cellules genetiquement modifiees presentant de faibles taux de proteines de classe i du complexe majeur d'histocompatibilite sur leur surface - Google Patents

Transplantation de cellules genetiquement modifiees presentant de faibles taux de proteines de classe i du complexe majeur d'histocompatibilite sur leur surface

Info

Publication number
EP0820311A4
EP0820311A4 EP96912564A EP96912564A EP0820311A4 EP 0820311 A4 EP0820311 A4 EP 0820311A4 EP 96912564 A EP96912564 A EP 96912564A EP 96912564 A EP96912564 A EP 96912564A EP 0820311 A4 EP0820311 A4 EP 0820311A4
Authority
EP
European Patent Office
Prior art keywords
cells
genetically modified
transplantation
class
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96912564A
Other languages
German (de)
English (en)
Other versions
EP0820311A1 (fr
Inventor
Gillis R Otten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of EP0820311A1 publication Critical patent/EP0820311A1/fr
Publication of EP0820311A4 publication Critical patent/EP0820311A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Des cellules de mammifères sont modifiées génétiquement par introduction de gènes codant des protéines à régulation négative du complexe majeur d'histocompatibilité (CMH) issues de virus. Les cellules appropriées pour une transplantation sont prélevées sur un donneur puis transfectées par un vecteur d'expression codant une ou plusieurs protéines à régulation négative du CMH issues de virus. Les cellules du donneur génétiquement modifiées sont développées ex vivo, lorsque cela se révêle nécessaire, puis transplantées sur le récepteur. Les taux plus faibles de protéines de classe I du CMH permettent aux cellules transplantées de survivre dans des conditions où des cellules non modifiées génétiquement feraient l'objet d'une offensive du système immunitaire du récepteur. Les cellules du donneur peuvent en outre être modifiées pour cibler des cellules ou pour renforcer la fonction effectrice des cellules du donneur chez le récepteur.
EP96912564A 1995-04-04 1996-04-03 Transplantation de cellules genetiquement modifiees presentant de faibles taux de proteines de classe i du complexe majeur d'histocompatibilite sur leur surface Withdrawn EP0820311A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41610695A 1995-04-04 1995-04-04
US416106 1995-04-04
PCT/US1996/004648 WO1996031241A1 (fr) 1995-04-04 1996-04-03 Transplantation de cellules genetiquement modifiees presentant de faibles taux de proteines de classe i du complexe majeur d'histocompatibilite sur leur surface

Publications (2)

Publication Number Publication Date
EP0820311A1 EP0820311A1 (fr) 1998-01-28
EP0820311A4 true EP0820311A4 (fr) 2002-09-25

Family

ID=23648556

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96912564A Withdrawn EP0820311A4 (fr) 1995-04-04 1996-04-03 Transplantation de cellules genetiquement modifiees presentant de faibles taux de proteines de classe i du complexe majeur d'histocompatibilite sur leur surface

Country Status (7)

Country Link
EP (1) EP0820311A4 (fr)
JP (1) JPH11503024A (fr)
KR (1) KR19980703665A (fr)
AU (1) AU712415B2 (fr)
CA (1) CA2217297A1 (fr)
NO (1) NO974596L (fr)
WO (1) WO1996031241A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047914A2 (fr) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Gene us6 issu du cytomegalovirus humain
WO1999036562A1 (fr) * 1998-01-14 1999-07-22 Human Gene Therapy Research Institute Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique
EP1020520A1 (fr) * 1999-01-15 2000-07-19 Introgene B.V. Prévention d'élimination immunologiques des cellules du corps mammifère, molécules PML mutantes utiles à cet effet
DK3333265T3 (da) 2010-05-14 2020-04-27 Univ Oregon Health & Science Rekombinante hcmv- og rhcmv-vektorer der koder for et heterologt antigen isoleret fra hepatitis b-virus og anvendelser deraf
US20120020885A1 (en) * 2010-07-26 2012-01-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware MHC-Less cells
WO2012170765A2 (fr) 2011-06-10 2012-12-13 Oregon Health & Science University Glycoprotéines de cmv et vecteurs recombinants cmv
KR101996427B1 (ko) 2014-07-16 2019-07-04 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
KR20170136512A (ko) 2015-02-10 2017-12-11 오레곤 헬스 앤드 사이언스 유니버시티 넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물
JP7133468B2 (ja) 2015-11-20 2022-09-08 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ マイクロｒｎａ認識エレメントを含むｃｍｖベクター
EP3529363A4 (fr) 2016-10-18 2020-05-06 Oregon Health & Science University Vecteurs de cytomégalovirus déclenchant des lymphocytes t limités par des molécules e de complexe majeur d'histocompatibilité
US20200399343A1 (en) * 2017-04-19 2020-12-24 Allogene Therapeutics, Inc. Improved t cell compositions and methods
WO2019167973A1 (fr) * 2018-03-01 2019-09-06 Kyoto University Inhibiteur d'évolution de cycle cellulaire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2074825C (fr) * 1990-12-14 2005-04-12 Daniel J. Capon Chaines chimeriques pour cheminements de signaux de recepteurs
WO1994016065A1 (fr) * 1992-12-31 1994-07-21 Exemplar Corporation Production de cellules destinees a la transplantation et reduisant le rejet du greffon par l'hote, et cellules ainsi obtenues

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EFRAT SHIMON ET AL: "Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 15, July 1995 (1995-07-01), 1995, pages 6947 - 6951, XP002187510, ISSN: 0027-8424 *
HORWITZ MARSHALL S ET AL: "Multiple functions of adenovirus E3 immunoregulatory genes: Effects on acute viral pathogenesis and prolongation of survival of pancreatic islet allografts.", JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, no. 19A, 1995, Keystone Symposium on Molecular Aspects of Viral Immunity;Keystone, Colorado, USA; January 16-23, 1995, pages 279, XP002187508, ISSN: 0733-1959 *
RAWLE F C ET AL: "MOUSE ANTI-ADENOVIRUS CYTOTOXIC T LYMPHOCYTES INHIBITION OF LYSIS BY E3 GP19K BUT NOT E3 14.7K", JOURNAL OF IMMUNOLOGY, vol. 143, no. 6, 1989, pages 2031 - 2037, XP002187509, ISSN: 0022-1767 *
See also references of WO9631241A1 *
SESTER MARTINA ET AL: "Conserved cysteine residues within the E3/19K protein of adenovirus type 2 are essential for binding to major histocompatibility complex antigens.", JOURNAL OF VIROLOGY, vol. 68, no. 9, 1994, pages 5423 - 5432, XP002187511, ISSN: 0022-538X *

Also Published As

Publication number Publication date
AU712415B2 (en) 1999-11-04
NO974596L (no) 1997-12-03
CA2217297A1 (fr) 1996-10-10
NO974596D0 (no) 1997-10-03
JPH11503024A (ja) 1999-03-23
WO1996031241A1 (fr) 1996-10-10
AU5533896A (en) 1996-10-23
KR19980703665A (ko) 1998-12-05
EP0820311A1 (fr) 1998-01-28

Similar Documents

Publication Publication Date Title
EP0820311A4 (fr) Transplantation de cellules genetiquement modifiees presentant de faibles taux de proteines de classe i du complexe majeur d'histocompatibilite sur leur surface
WO1998002546A3 (fr) VACCINATION A L'ADN CONTRE L'INFECTION DUE A $i(CHLAMYDIA)
AU2812484A (en) Dna vectors and there use in recombinant dna technology
EP0945515A3 (fr) Production de protéines par recombinaison homologue
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
AU5308698A (en) Design principle for constructing expression constructs for gene therapy
WO1995027071A3 (fr) Systeme supervecteur adenoviral
EP1923467A3 (fr) Vecteurs d'adénovirus pour thérapie génétique
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
ES2121794T3 (es) Procedimiento de transferencia de genes por medio de retrotransposones.
AU2001278797A1 (en) Expression vector using for animal cell
NZ504185A (en) Expression of endogenous genes by non-homologous recombination of a vector construct with cellular DNA
WO2006096989A3 (fr) Vecteurs d'expression pour l'expression genetique transitoire et cellules mammaliennes les exprimant
EP0338266A3 (fr) Vecteur chromosomique artificiel
IL148785A0 (en) Vectors and methods for recombinant protein expression
DK0842289T3 (da) Homolog rekombination i eukaryote celler med inaktiveret fejlparringsreparation
DE3853474D1 (de) Vektor zur integrationsstellenunabhängigen genexpression in säugetier-wirtszellen.
WO1999021976A3 (fr) Generation rapide de lignees cellulaires mammiferes stables produisant des niveaux eleves de proteines recombinantes
KR930701610A (ko) 미생물의 세포, 조직 또는 숙주 지향성을 변화시키는 방법, 이 방법으로 수득된 재조합 미생물, 및 의학 및 수의학분야에서 이들을 사용하는 방법
PT941329E (pt) Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
AU5318496A (en) Adenovirus vectors for gene therapy
GB9825096D0 (en) Cells,culture methods and their uses
ES2004099A6 (es) Procedimiento de preparacion de polipeptidos biologicamente activos
EP2281892A3 (fr) Procédé de préparer des polypeptides dans de cellules Trichoderma avec des déficiences respiratoires
AU1935399A (en) Nucleotide and protein sequence of mammastatin and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 48/00 A, 7C 12N 5/10 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020701

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030301